252 related articles for article (PubMed ID: 21729023)
1. Increased immunoreactivity of membrane type-1 matrix metalloproteinase (MT1-MMP) and β-catenin in high-risk basal cell carcinoma.
Oh ST; Kim HS; Yoo NJ; Lee WS; Cho BK; Reichrath J
Br J Dermatol; 2011 Dec; 165(6):1197-204. PubMed ID: 21729023
[TBL] [Abstract][Full Text] [Related]
2. Expression of CXCR4, MMP-13 and β-catenin in different histological subtypes of facial basal cell carcinoma.
Ciurea ME; Cernea D; Georgescu CC; Cotoi OS; Pătraşcu V; Pârvănescu H; Popa D; Pârvănescu V; Ciurea RN; Mercuţ R
Rom J Morphol Embryol; 2013; 54(4):939-51. PubMed ID: 24398989
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of COX-2 in recurrent basal cell carcinoma of the skin: a pilot study.
Karahan N; Baspinar S; Bozkurt KK; Caloglu E; Ciris IM; Kapucuoglu N
Indian J Pathol Microbiol; 2011; 54(3):526-31. PubMed ID: 21934214
[TBL] [Abstract][Full Text] [Related]
4. Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas.
Betti R; Menni S; Radaelli G; Bombonato C; Crosti C
J Dermatol; 2010 Jul; 37(7):611-6. PubMed ID: 20629826
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis.
Itatsu K; Zen Y; Ohira S; Ishikawa A; Sato Y; Harada K; Ikeda H; Sasaki M; Nimura Y; Nakanuma Y
Liver Int; 2007 Nov; 27(9):1174-84. PubMed ID: 17919228
[TBL] [Abstract][Full Text] [Related]
6. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2.
Zagrodnik B; Kempf W; Seifert B; Müller B; Burg G; Urosevic M; Dummer R
Cancer; 2003 Dec; 98(12):2708-14. PubMed ID: 14669293
[TBL] [Abstract][Full Text] [Related]
7. Expression of beta-catenin in basal cell carcinoma.
El-Bahrawy M; El-Masry N; Alison M; Poulsom R; Fallowfield M
Br J Dermatol; 2003 May; 148(5):964-70. PubMed ID: 12786827
[TBL] [Abstract][Full Text] [Related]
8. Protein expression of MMP-2 and MT1-MMP in actinic keratosis, squamous cell carcinoma of the skin, and basal cell carcinoma.
de Oliveira Poswar F; de Carvalho Fraga CA; Gomes ES; Farias LC; Souza LW; Santos SH; Gomez RS; de-Paula AM; Guimarães AL
Int J Surg Pathol; 2015 Feb; 23(1):20-5. PubMed ID: 24984957
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma.
Mylona E; Nomikos A; Magkou C; Kamberou M; Papassideri I; Keramopoulos A; Nakopoulou L
Histopathology; 2007 Feb; 50(3):338-47. PubMed ID: 17257129
[TBL] [Abstract][Full Text] [Related]
10. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
11. Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin.
Brasanac D; Boricic I; Todorovic V; Tomanovic N; Radojevic S
Br J Dermatol; 2005 Dec; 153(6):1166-75. PubMed ID: 16307653
[TBL] [Abstract][Full Text] [Related]
12. Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers.
Kerkelä E; Ala-aho R; Lohi J; Grénman R; M-Kähäri V; Saarialho-Kere U
Br J Cancer; 2001 Mar; 84(5):659-69. PubMed ID: 11237387
[TBL] [Abstract][Full Text] [Related]
13. Calcifications associated with basal cell carcinoma: prevalence, characteristics, and correlations.
Slodkowska EA; Cribier B; Peltre B; Jones DM; Carlson JA
Am J Dermatopathol; 2010 Aug; 32(6):557-64. PubMed ID: 20489568
[TBL] [Abstract][Full Text] [Related]
14. [Correlation of membrane type I matrix metalloproteinase (MT1-MMP) expression with clinicomorphological features of tumor front in squamous cell carcinoma of the larynx].
Starska K; Stasikowska O; Lukomski M; Lewy-Trenda I
Pol Merkur Lekarski; 2007 Sep; 23(135):188-91. PubMed ID: 18080692
[TBL] [Abstract][Full Text] [Related]
15. Atypical localization of membrane type 1-matrix metalloproteinase in the nucleus is associated with aggressive features of hepatocellular carcinoma.
Ip YC; Cheung ST; Fan ST
Mol Carcinog; 2007 Mar; 46(3):225-30. PubMed ID: 17219425
[TBL] [Abstract][Full Text] [Related]
16. Proteolytic activation of heparin-binding EGF-like growth factor by membrane-type matrix metalloproteinase-1 in ovarian carcinoma cells.
Koshikawa N; Mizushima H; Minegishi T; Eguchi F; Yotsumoto F; Nabeshima K; Miyamoto S; Mekada E; Seiki M
Cancer Sci; 2011 Jan; 102(1):111-6. PubMed ID: 20946474
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of basal cell carcinoma.
Hakverdi S; Balci DD; Dogramaci CA; Toprak S; Yaldiz M
Indian J Dermatol Venereol Leprol; 2011; 77(2):251. PubMed ID: 21393972
[TBL] [Abstract][Full Text] [Related]
18. Expression of p16 Protein in Cutaneous Basal Cell Carcinoma: Still far from Being Clearly Understood.
Bartoš V
Acta Dermatovenerol Croat; 2020 Jul; 28(1):43-44. PubMed ID: 32650852
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression.
O'Grady A; Dunne C; O'Kelly P; Murphy GM; Leader M; Kay E
Histopathology; 2007 Dec; 51(6):793-804. PubMed ID: 18042068
[TBL] [Abstract][Full Text] [Related]
20. WNT-1 expression in basal cell carcinoma of head and neck. An immunohistochemical and confocal study with regard to the intracellular distribution of beta-catenin.
Lo Muzio L; Pannone G; Staibano S; Mignogna MD; Grieco M; Ramires P; Romito AM; De Rosa G; Piattelli A
Anticancer Res; 2002; 22(2A):565-76. PubMed ID: 12014624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
